Business Wire

New Research from AMGTA Demonstrates Sustainable Benefits of Binder Jet 3D Printing

Share

The Additive Manufacturer Green Trade Association (“AMGTA”), a global advocacy group focused on promoting sustainable additive manufacturing (AM) industry practices, announced today the preliminary results of a life-cycle analysis study titled “Comparative Life-Cycle Assessment: Comparison of Casting vs Binder Jetting for an Industrial Part.” The study, commissioned by the AMGTA and conducted by the Yale School of the Environment (YSE) in partnership with Desktop Metal (NYSE: DM), a global leader in AM technologies for mass production, and Trane Technologies (NYSE: TT), a global climate innovator, analyzed a steel scroll chiller in an HVAC system from Trane to determine the comparative manufacturing impact of binder jet 3D printing versus traditional metal casting. The preliminary results confirmed a dramatic 38% reduction in greenhouse gas (GHG) emissions through the binder jetting process primarily driven by reduced energy demand during the production phase.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230728084474/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Desktop Metal’s binder jet 3D printing technology (Photo: Desktop Metal)

“Prior to this project, uncertainty about the life cycle emissions of binder jetting versus conventional manufacturing approaches was a barrier to AM adoption,” said Kevin Klug, Lead Additive Manufacturing Engineer for Trane Technologies. “With the results of this study, Trane Technologies is in a better position to comprehensively consider AM's cost, productivity and environmental impact earlier in a product's design cycle, when risk is lowest, and the potential benefits are highest.”

Key takeaways from the from the study include:

  • Significant Reduction in Greenhouse Gas Emissions. The additive process showed a 38% reduction in greenhouse gas emissions based on binder jetting as compared to traditional casting for the parts studied.
  • Importance of Energy Mix. Similar to previous findings, the study found that the manufacturing facility’s energy mix at the location of generation, and whether that energy grid was produced using sustainable means, had a significant impact on GHG emissions.
  • Negligible Value of Redesign for Lightweighting. The study found that the potential benefits of redesigning the scroll chiller for lightweighting using a lattice-type structure were insignificant with respect to GHG emissions. The overall dimensions of the parts being produced, and the efficient use of print volumes, played a much more important factor than lightweighting. Lightweighting may provide environmental benefits in the use phase which is not included in this study.
  • Material Production Impacts. While this study showed the environmental impacts of source powder production were approximately twice that for casting steel, such an increase represented a small portion of overall GHG emissions and did not play a significant role in the overall findings.
  • Overall, Binder Jetting Produced a More Sustainable Part. The dramatic reduction of GHG emissions from energy demand by binder jetting versus traditional manufacturing was by far the most important finding of the YSE study.

“The release of these findings is significant for the AM industry and for companies in the broader manufacturing sector who are looking for more sustainable production methods,” said Sherri Monroe, the AMGTA’s Executive Director. “With this study, we are able to quantify the reduced energy demand of binder jetting versus traditional casting while possibly providing some surprises in the negligible impact offered by lightweighting in this specific use case.”

One of the drivers behind double-digit annual growth in additive manufacturing over the past decade has been the adoption of binder jetting across multiple industries, driven by cost advantages, large volume production, and the potential for sustainability gains.

“We’re delighted to have another piece of independent, third-party research that validates how binder jetting is a greener approach to metal part production,” said Jonah Myerberg, Chief Technology Officer, Desktop Metal. “Harmful emissions from traditional metal manufacturing need to be lowered with innovative technology approaches, but manufacturers need sound data—not greenwashing—to make good choices about how they produce their metal products. This new study from Yale, Trane Technologies and AMGTA demonstrates what our team at Desktop Metal has long believed based on our hands-on experience: binder jetting is a greener way to manufacture metal parts.”

The two-year YSE study analyzed the cradle-to-gate manufacturing life cycle of a scroll set comprised of a fixed scroll and orbiting scroll manufactured by Trane Technologies as part of an HVAC system. The AMGTA commissioned the study in 2021 to better understand the potential for binder jetting to replace traditional sand casting as a more sustainable method of production. The study evaluated a traditional casting process followed by machining, plating, and finishing steps in Mexico. The same scroll set design was evaluated through an additive binder jetting process of 3D printing, curing, and sintering followed by the same plating and finishing steps in the same location in Mexico.

The results of the study showed a 38% reduction in GHG emissions for the additive manufacturing process as compared to the traditional casting-based method. Due to the nature of the binder jetting, YSE’s researchers concluded that a redesign for lightweighting via a lattice-type structure may not necessarily lead to additional reductions in GHG emissions, primarily because the majority of electricity consumed related to printing, curing and sintering steps would not be impacted by lattice-type structures. The analysis suggests a 10% mass reduction in the scroll set would lead to a 1% reduction in GHG emissions.

Lifecycle GHG emissions were significantly impacted by the local energy mix at the site of production. For this study, both the traditionally manufactured part set, and the additively manufactured part set, were evaluated at the same location with the same energy mix. Researchers also evaluated additional potential production locations and their corresponding energy mixes. The findings indicate that such sensitivity to the grid “cleanness” needs to be considered when comparing AM with traditional processes to ensure a valid conclusion. While production in a more sustainable energy location provides environmental benefits for both production processes, the difference in environmental impacts between the methods diminishes as the energy mix becomes more “green.” Production volumes also play a significant role in GHG emissions of additive manufacturing especially for less efficient use of build volumes and small batch operations.

“Trane Technologies is committed to boldly challenging what's possible for a sustainable world,” added Kevin Klug. “That includes designing advanced climate control solutions that can be manufactured and operated with reduced environmental impact. Metal additive manufacturing (AM) will become an increasingly viable tool in that pursuit, and binder jetting's comparably higher speed and lower cost among AM technologies make it particularly promising for manufacturing HVAC components at relevant production volumes.”

“This study in collaboration with Desktop Metal is a clear win for manufacturers like Trane which are exploring more sustainable manufacturing options. Binder jetting is a proven technology with clear and quantifiable advantages over traditional methods,” Sherri Monroe said. “We appreciate Trane’s leadership in pursuing more sustainable practices, their participation in this study, their willingness to share their processes and data, and interest in sharing this information with the broader manufacturing community.”

Highlights from the study can be found on the AMGTA’s website, with full results expected to be published in early 2024 following a peer review process. The AMGTA says it expects to publish additional independent research throughout 2023. Additional information on this study and others conducted by the AMGTA can be found on the AMGTA website, www.AMGTA.org.

About the AMGTA

The AMGTA was launched in 2019 to better understand and promote the environmental benefits of additive manufacturing across the global economy. AMGTA members represent the entirety of the manufacturing spectrum - from design and raw materials to end products and users - focused on innovating better, more sustainable, and financially advantageous products through best additive practices. For more information, please contact Sherri Monroe or visit www.amgta.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Sherri Monroe
smonroe@amgta.org
954.308.0888

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 11:00:00 EET | Press release

Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single

Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 11:00:00 EET | Press release

Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 10:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap

DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 09:30:00 EET | Press release

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical

Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 04:41:00 EET | Press release

Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye